This 90 minute in-depth webinar discusses the FDA Warning Letters and recent high-profile recalls indicate major cGMP deficiencies in big name device and pharma companies, many going back to insufficient, poor or non-existent V&V planning.
And now, the FDA is taking an even tougher stance.
And now, the FDA is taking an even tougher stance.
